secwatch.observer — SEC 8-K summary
======================================

Issuer:     LivaNova PLC (LIVN)
CIK:        0001639691
Form:       8-K
Filed at:   2026-02-25T23:59:59+00:00
Accession:  0001639691-26-000006
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LivaNova Q4 revenue $360.9M (+12.1%); FY25 adj. EPS $3.90; guides FY26 rev. growth 6-7%
--------------------------------------------------------------------------------

- Q4 GAAP EPS $0.56; adjusted EPS $0.86. Full-year revenue $1.39B, +10.7% reported.
- Full-year GAAP diluted loss per share $4.45 includes $365.6M SNIA environmental charge.
- Full-year adjusted diluted EPS $3.90; adjusted free cash flow $183.3M.
- 2026 guidance: constant-currency revenue growth 6-7%; adjusted EPS $4.15-$4.25.
- CMS increased reimbursement for VNS Therapy DRE procedures effective Jan 1, 2026; FDA approved cloud-based digital health platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1639691/000163969126000006/0001639691-26-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1639691/000163969126000006/livn-20260225.htm
  HTML page:      https://secwatch.observer/filing/0001639691-26-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer